Pralsetinib
Back to searchMolecule Structure
Scientific Name
Pralsetinib
Description of the Drug
Pralsetinib is a RET receptor tyrosine kinase inhibitor for the treatment of metastatic RET-driven non-small cell lung cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15822
http://www.drugbank.ca/drugs/DB15822
Brand Name(s)
Gavreto
Company Owner(s)
Genentech Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET | CHIMERIC PROTEIN | INHIBITOR | CHEMBL3430904 |
| Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET | CHIMERIC PROTEIN | INHIBITOR | CHEMBL3430888 |
| Tyrosine-protein kinase receptor RET | SINGLE PROTEIN | INHIBITOR | CHEMBL2041 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL18789229 |
| DrugBank | DB15822 |
| Guide to Pharmacology | 10033 |
